ABLYNX SUCCESSFULLY RAISES ?50 MILLION WITH SECONDARY PUBLIC OFFERING - FINAL PRICE: ?7.5 PER SHARE
(Thomson Reuters ONE) -
This announcement is an advertisement and not a prospectus. Investors should not
subscribe for or purchase any securities referred to in this announcement except
on the basis of information in the prospectus published by Ablynx NV (the
"Company") on 26 February 2010 (which is supplemented by an addendum approved by
the CBFA on 7 March 2010) in connection with the Offering of offered shares and
the admission of the new shares and VVPR strips to trading on Euronext Brussels
(the "Prospectus").
GHENT, Belgium - 15 March 2010 - Ablynx, the biopharmaceutical company focused
on the discovery and development of Nanobodies(®), announced today that it has
successfully completed its Secondary Public Offering (the "SPO" or "Offering")
raising ?50 million.
The offered shares were priced at ?7.5 per share. As a result of the Offering,
6,666,667 new shares, equivalent to ?50 million, will be issued by Ablynx.
Additionally, 400,000 over-allotment shares, equivalent to ?3 million, will be
allocated. The over-allotment shares are existing shares and if the
over-allotment option is exercised in full, this will result in the sale of the
over-allotment shares by the Lending Shareholders.
KBC Securities NV and UBS Investment Bank acted as Joint Global Coordinators and
Joint Bookrunners, while Piper Jaffray Ltd. acted as Co-Manager to the Offering
and while KBC Bank NV and Kempen & Co NV acted as selling agent.
Commenting on today's announcement, Dr Edwin Moses, Ablynx's Chairman and Chief
Executive Officer said:
"We are delighted to have successfully completed our secondary public offering
and to have been able to attract a wide range of new specialist and generalist
investors from Europe and the USA as well as receiving significant support from
existing investors. I believe this is a reflection of the strength of our
pipeline and our well validated Nanobody platform combined with the fact that we
have delivered on all the promises we made at the IPO. We will now have
increased flexibility to advance programmes through to clinical
proof-of-concept, potentially commercialise our orphan drug programme, ALX-0681,
ourselves and/or co-invest in development alongside our pharmaceutical partners,
in return for a greater share of the value we create. We believe all these
activities will considerably enhance Ablynx's future potential."
For more information, please contact:
Contacts at Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e: wim.ottevaere(at)ablynx.com
For international media enquiries:
College Hill Life Sciences
Sue Charles, Justine Lamond
t: +44 (0)20 7866 7857
e: ablynx(at)collegehill.com
[HUG#1393717]
Complete version of the press release: http://hugin.info/137912/R/1393717/350776.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2010 - 01:00 Uhr
Sprache: Deutsch
News-ID 1011341
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Ghent
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX SUCCESSFULLY RAISES ?50 MILLION WITH SECONDARY PUBLIC OFFERING - FINAL PRICE: ?7.5 PER SHARE
"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
